KEYNOTE-522: Neoadjuvant and adjuvant pembrolizumab for early TNBC

KEYNOTE 522: pembrolizumab as neoadjuvant treatment for early TNBC

KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...

Remaining questions on the use of neoadjuvant pembrolizumab in early TNBC following KEYNOTE-522

Immunotherapy Keytruda Shows Benefit in Early Triple-Negative Breast Cancer

KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer

The challenges of treating early-stage TNBC

De-escalation of therapy in early-stage TNBC

What to do in patients with early-stage TNBC who have not achieved a pCR?

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer

KEYNOTE-355: pembrolizumab in triple-negative breast cancer

Human trials begin for triple negative breast cancer vaccine

Clinical Trials for Metastatic Triple Negative Breast Cancer

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breas...

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC

Early TNBC - Pembrolizumab + chemotherapy: Pathologic complete response in key subgroups

GS1-01: "Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant..."

Personalizing approaches in early-stage TNBC

Emerging immunotherapy beyond checkpoint inhibitors for TNBC